Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia/lymphoma

Affiliations

¹ University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
² Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
³ Massachusetts General Hospital, Boston, Massachusetts, USA.
⁴ H. Lee Moffitt Cancer Center at Memorial Healthcare System, Pembroke Pines, Florida, USA.
⁵ Boston University Chobanian & Avesidian School of Medicine, Boston Medical Center, Boston, Massachusetts, USA.
⁶ Dana-Farber Cancer Institute, Bing Center for Waldenström Macroglobulinemia, Boston, Massachusetts, USA.

Christopher Dittus et al. Br J Haematol. 2025.

. 2025 Jun 3.

doi: 10.1111/bjh.20177. Online ahead of print.

¹ University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
² Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
³ Massachusetts General Hospital, Boston, Massachusetts, USA.
⁴ H. Lee Moffitt Cancer Center at Memorial Healthcare System, Pembroke Pines, Florida, USA.
⁵ Boston University Chobanian & Avesidian School of Medicine, Boston Medical Center, Boston, Massachusetts, USA.
⁶ Dana-Farber Cancer Institute, Bing Center for Waldenström Macroglobulinemia, Boston, Massachusetts, USA.

No abstract available

Keywords: T‐cell lymphoma; acute leukaemia; clinical trials; lymphoid malignancies.

References

1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443–459.
1. Goncalves DU, Proietti FA, Ribas JGR, Araújo MG, Pinheiro SR, Guedes AC, et al. Epidemiology, treatment, and prevention of human T‐cell leukemia virus 1‐associated diseases. Clin Microbiol Rev. 2010;23(3):577–589.
1. Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN‐35) for relapsed CD30‐positive lymphomas. N Engl J Med. 2010;363:1812–1821.
1. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN‐35) in patients with relapsed or refractory systemic anaplastic large‐cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–2196.
1. Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30‐positive peripheral T‐cell lymphoma (ECHELON‐2): a global, double‐blind, randomised, phase 3 trial. Lancet. 2019;393:229–440.